Amanta Healthcare IPO

It operates an ISO and WHO-GMP certified manufacturing facility, which has a significant capacity of 56.6 million LVP, 209.1 million SVP, and 66.2 million SteriPort bottles annually.

The company demonstrates strong operational efficiency with 96% utilization for LVP, 91% for SVP, and 87% for SteriPort in FY25. This indicates effective use of its manufacturing assets.

Amanta Healthcare produces parenteral products across three business units with margin profiles ranging from 20% to over 60% depending on the product. This diversified margin potential contributes to profitability.

Though the company has high debt compared to its earnings, it managed to reduce it significantly from ₹215.7 crore in FY23 to ₹195 crore in FY25. Subsequently, its debt-to-equity ratio improved from 3.43 to 2.02 during the same period.

Amanta Healthcare manufactures diverse sterile liquid products, including IV fluids and ophthalmics. It serves 21 countries and has 47 products registered across 120 international jurisdictions, demonstrating broad market reach and product diversity.

The company benefits from an experienced management team, including its Chairman and MD, and a large workforce of 1,718 personnel as of March 31, 2025. This expertise drives strategy and operational efficiency.

All products are made at a single facility in Gujarat. Any disruption due to power issues, accidents, or natural disasters at this sole site could severely impact its entire production, business, and cash flows.

Amanta Healthcare faces high finance costs, which were 45.78% of its EBITDA (operating profit) in FY25. Its debt-to-equity ratio was 2.02 in FY25, indicating significant debt that could limit future borrowing and profitability.

The company relies significantly on a few customers; its top 10 customers contributed 28.59% of revenue in FY25. Losing these key customers or a drop in their orders could severely impact its revenue and financial health.

Its competitor, Denis Chem Lab Limited, had a higher PAT Margin of 4.66% in FY25 compared to Amanta Healthcare's 3.86%. This suggests that Denis Chem Lab is more efficient at converting revenue into net profit.

International sales, which made up 33.06% of revenue in FY25, expose it to foreign currency fluctuations. While hedging occurs, unmitigated currency swings could negatively affect its financial results and cash flows from exports and imports.